HomeAI · summaries
Storia in 4 fonti
Novo Nordisk stops 2 more trials for its heart disease medicine in fresh setback
Earlier this year, Novo said ziltivekimab failed to reduce the risk of heart attacks and strokes, diminishing expectations for other ongoing studies.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
swissinfo.ch
Novartis Drug Fails Key Test for New Heart Disease Approach
(Bloomberg) -- A Novartis AG drug billed as a potential blockbuster failed to reduce the risk of heart attacks and strokes in a final-stage trial, marking a major setback for a…
- ·
endpoints.news
Updated: Novo Nordisk cans two more trials of IL-6 heart drug for futility
Novo Nordisk stops two more ziltivekimab heart trials, HERMES and ATHENA, after July's ZEUS failure casts doubt on IL-6 inhibition in heart disease.
